Binhui Biopharmaceutical Co., Ltd.

武汉滨会生物科技股份有限公司

China-based biotechnology company developing oncolytic virus cancer immunotherapies, including core clinical-stage candidate BS001 (OH2 Injection), an HSV-2-based oncolytic virus for advanced solid tumors, plus additional clinical and preclinical pipeline candidates.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Overlapping customers and suppliers
• Reliance on platforms, partners or licences
• Outsourced production (OEM / contract manufacturing)
• Losses and path to profitability
• Cash burn and runway
• Non-IFRS measures and adjustments
• Material share-based payments
• Chapter 18A biotech